These projections assume Lilly continues executing on Foundayo, retatrutide, and pipeline acquisitions
In January 2026, Quva Pharma announced a new group purchasing agreement with Premier, Inc., effective November 1, 2025, thus allowing Premier members to access special pricing and terms for outsourced compounded preparations
see GLP-1 and hair loss: causes and prevention
A 2024 review describes the connection between GLP1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications
Louis Park, Minnesota, discussed how type 2 diabetes is a common condition among people with binge eating disorder